Methofill (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to produce tetrahydrofolate, a cofactor for DNA synthesis. By limiting nucleotide formation, it reduces proliferation of immune cells and rapidly dividing tissues, providing anti‑inflammatory and anti‑cancer effects.

The dosage of Methofill is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Methofill is classified as Pregnancy Category X because it can cause severe fetal malformations and miscarriage. It is contraindicated in pregnancy and should not be used by nursing mothers, as it may be excreted in breast milk and harm the infant.

To request Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methofill (methotrexate) is often considered a first‑line DMARD due to its proven efficacy, oral or injectable formulations, and cost‑effectiveness. Compared with biologic agents, it has a broader safety profile but may require more laboratory monitoring. Choice of therapy depends on disease severity, patient comorbidities and treatment goals.

Methofill should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and light. Do not freeze the product. Keep it out of reach of children and handle with clean, dry hands to maintain sterility.

Methofill is supplied for subcutaneous injection. The healthcare provider prepares the dose using a sterile syringe and injects it into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique and the prescribed dosing schedule.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to life‑threatening infections, renal failure, and rare anaphylactic reactions. Patients should be monitored regularly for liver enzymes, lung function, blood counts and kidney parameters to detect these complications early.

Methofill is contraindicated in pregnant women, nursing mothers, patients with severe liver or kidney disease, uncontrolled infections, and individuals with known hypersensitivity to methotrexate or any component of the formulation. A thorough medical assessment is required before initiating therapy.